Emerging research suggest this peptide, a dual stimulator targeting both incretin and GIP , could provide a significant development for obesity treatment. Preliminary human trials have demonstrated impressive losses in visceral fat , potentially exceeding existing obesity treatments. However , additional evaluation is necessary to thoroughly assess